Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director · CHIEF EXECUTIVE OFFICER | June 30, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SPRUCE BIOSCIENCES, INC.
Report date June 30, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,270 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 266 · Balance 19,270 F1: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 9, 2026 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 266 | $4.53 | $1,205.11 |
DisclosureSEC source: 0001903669-26-000006 · form4-07092026_040701.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,270 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:43 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 4,690 | $4.53 | $21,248.05 |
DisclosureSEC source: 0001903669-26-000002 · form4-01052026_090149.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,004 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The Reporting Person acquired the maximum shares allowable pursuant to Section 423 of the Internal Revenue Code. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:56 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 1,196 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000010 · form4-12172025_091239.xml · derivative · entry 8 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,392 Underlying: Common Stock · 1,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares. F3 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:56 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 1,480 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000010 · form4-12172025_091239.xml · derivative · entry 7 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,480 Underlying: Common Stock · 1,480 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of the Issuer. F1 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares. F1 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:56 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 608 | $80.67 | $49,047.36 |
DisclosureSEC source: 0001903669-25-000010 · form4-12172025_091239.xml · nonDerivative · entry 4 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,314 F3 · shares: On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:56 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 1,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000010 · form4-12172025_091239.xml · nonDerivative · entry 3 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares. F2 · price: Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:56 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 752 | $80.67 | $60,663.84 |
DisclosureSEC source: 0001903669-25-000010 · form4-12172025_091239.xml · nonDerivative · entry 2 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,726 F1 · shares: On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:56 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 1,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000010 · form4-12172025_091239.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares. F2 · price: Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:03 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 4,950 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000006 · form4-12132025_121210.xml · derivative · entry 7 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,850 Underlying: Common Stock · 4,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. F3 · derivative.expiration_date: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:03 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 19,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000006 · form4-12132025_121210.xml · derivative · entry 6 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,800 Underlying: Common Stock · 19,800 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. F3 · derivative.expiration_date: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:03 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 2,194 | $88.41 | $193,971.54 |
DisclosureSEC source: 0001903669-25-000006 · form4-12132025_121210.xml · nonDerivative · entry 4 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,998 F3 · shares: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. Read SEC document |
| December 11, 2025 Filed Dec 13, 2025 00:03 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 4,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000006 · form4-12132025_121210.xml · nonDerivative · entry 3 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: 25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:52 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $344.25 | Not disclosed |
DisclosureSEC source: 0001903669-25-000008 · form4-12152025_111200.xml · derivative · entry 2 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 3, 2022, with 1/4th of the shares vested on January 3, 2023 and 1/36th of the remaining shares vesting on a monthly basis, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 23:52 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001903669-25-000008 · form4-12152025_111200.xml · derivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 3, 2022, with 1/4th of the shares vested on January 3, 2023 and 1/36th of the remaining shares vesting on a monthly basis, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| December 11, 2025 Filed Dec 17, 2025 21:56 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,666 | Not disclosed Strike: $344.25 | Not disclosed |
DisclosureSEC source: 0001903669-25-000010 · form4-12172025_091239.xml · derivative · entry 6 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,666 shares Expires 2032-01-02 F5 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F6 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F4 · derivative.exercise_date: The shares vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). 50% or 1,666 shares of the total shares vested on November 26, 2023. 50% or 1,666 shares of the total shares did not vest as the relevant performance goal was not achieved. Read SEC document |
| December 11, 2025 Filed Dec 17, 2025 21:56 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 1,666 | Not disclosed Strike: $104.13 | Not disclosed |
DisclosureSEC source: 0001903669-25-000010 · form4-12172025_091239.xml · derivative · entry 5 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,666 Underlying: Common Stock · 1,666 shares Expires 2032-01-02 F5 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date. F6 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options. F4 · derivative.exercise_date: The shares vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). 50% or 1,666 shares of the total shares vested on November 26, 2023. 50% or 1,666 shares of the total shares did not vest as the relevant performance goal was not achieved. Read SEC document |
| December 10, 2025 Filed Dec 13, 2025 00:03 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 1,196 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000006 · form4-12132025_121210.xml · derivative · entry 5 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,588 Underlying: Common Stock · 1,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares. F1 · derivative.expiration_date: On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares. Read SEC document |
| December 10, 2025 Filed Dec 13, 2025 00:03 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 428 | $85.67 | $36,666.76 |
DisclosureSEC source: 0001903669-25-000006 · form4-12132025_121210.xml · nonDerivative · entry 2 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,242 F1 · shares: On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares. Read SEC document |
| December 10, 2025 Filed Dec 13, 2025 00:03 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 1,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000006 · form4-12132025_121210.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement. On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 4,784 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000003 · form4-10222025_041001.xml · derivative · entry 4 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,784 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares. F1 · derivative.expiration_date: On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 4,784 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000003 · form4-10222025_041001.xml · derivative · entry 3 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,784 Underlying: Common Stock · 4,784 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares. F1 · derivative.expiration_date: On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 1,539 | $148.16 | $228,018.24 |
DisclosureSEC source: 0001903669-25-000003 · form4-10222025_041001.xml · nonDerivative · entry 2 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,474 F1 · shares: On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 20:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 4,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001903669-25-000003 · form4-10222025_041001.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 111,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · derivative · entry 9 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 111,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 111,000 RSUs vested, with 39,605 shares withheld for taxes, resulting in a net issuance of 71,395 shares. F3 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 111,000 RSUs vested, with 39,605 shares withheld for taxes, resulting in a net issuance of 71,395 shares. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 89,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · derivative · entry 8 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,100 Underlying: Common Stock · 89,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional F4 · balance_after: Represents the aggregate balance of time-based RSUs. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 39,605 | $0.39 | $15,394.46 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 6 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,191 F3 · shares: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 111,000 RSUs vested, with 39,605 shares withheld for taxes, resulting in a net issuance of 71,395 shares. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 111,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 5 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 111,000 RSUs vested, with 39,605 shares withheld for taxes, resulting in a net issuance of 71,395 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 32,005 | $0.39 | $12,440.34 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 4 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,796 F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional Read SEC document |
| December 16, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 89,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 3 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 358,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · derivative · entry 7 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,800 Underlying: Common Stock · 358,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional F1 · derivative.expiration_date: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 128,020 | $0.54 | $68,746.74 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 2 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,101 F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional Read SEC document |
| December 10, 2024 Filed Dec 21, 2024 01:28 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 358,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029999 · form4-12212024_011208.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 14, 2023, the Reporting Person was granted a total of 717,600 RSUs. 50% or 358,800 of the total RSUs are performance-based and since certain specified performance goals were met, they all vested on December 10, 2024. An addition of 50% or 358,800 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2024, 89,700 shares vested and 32,005 shares were withheld for taxes, resulting in a net issuance of 57,695 shares. An additional F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:27 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 358,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008264 · form4-03182024_080323.xml · derivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,800 Underlying: Common Stock · 358,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of SPRB common stock. F2 · derivative.exercise_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective. F2 · derivative.expiration_date: Subject to the Reporting Person's Continuous Service as of each such vesting date, 25% of the total number of RSUs vests upon each of the first, second, third and fourth anniversaries of the achievement of a specified clinical development objective. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionRestricted Stock Units · Derivative | 111,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059053 · doc4.xml · derivative · entry 4 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,000 Underlying: Common Stock · 111,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F1 · derivative.exercise_date: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 111,000 RSUs vested, with 38,384 shares being withheld for taxes, resulting in a net issuance of 72,616 shares. F1 · derivative.expiration_date: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 111,000 RSUs vested, with 38,384 shares being withheld for taxes, resulting in a net issuance of 72,616 shares. F5 · balance_after: Represents the aggregate balance of 333,000 time-based RSUs. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Tax withholdingCommon Stock | 38,384 | $1.66 | $63,717.44 |
DisclosureSEC source: 0001209191-23-059053 · doc4.xml · nonDerivative · entry 2 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,321 F1 · shares: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 111,000 RSUs vested, with 38,384 shares being withheld for taxes, resulting in a net issuance of 72,616 shares. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | Exercise / conversionCommon Stock | 111,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059053 · doc4.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On December 5, 2022, the Reporting Person was granted 444,000 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs to vest on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2023, 111,000 RSUs vested, with 38,384 shares being withheld for taxes, resulting in a net issuance of 72,616 shares. F2 · price: Each RSU represents a contingent right to receive one share of SPRB common stock. Read SEC document |
| December 14, 2023 Filed Dec 19, 2023 01:15 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 717,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059053 · doc4.xml · derivative · entry 3 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 717,600 Underlying: Common Stock · 717,600 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of SPRB common stock. F3 · derivative.exercise_date: 358,800 of the RSUs shall vest as to 25% on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.exercise_date: 358,800 of the RSUs shall vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F3 · derivative.expiration_date: 358,800 of the RSUs shall vest as to 25% on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F4 · derivative.expiration_date: 358,800 of the RSUs shall vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| November 26, 2023 Filed Nov 29, 2023 00:00 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-23-056836 · doc4.xml · derivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-02 F1 · balance_after: On January 3, 2022, the Reporting Person was granted a stock option to purchase 250,000 shares of the Issuer's common stock. The shares subject to the stock option shall vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Certain specified performance goals were met, resulting in the vesting of 125,000 shares subject to the stock option. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 22:01 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 20,000 | $0.98 | $19,550.00 |
DisclosureSEC source: 0001209191-23-041260 · doc4.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,705 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 30, 2022 Filed Jan 6, 2023 01:12 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantCommon Stock | 14,705 | $0.93 | $13,716.82 |
DisclosureSEC source: 0001209191-23-002152 · doc4.xml · nonDerivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,705 F1 · shares: Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The Reporting Person acquired the maximum shares allowable pursuant to Section 423 of the Internal Revenue Code. Read SEC document |
| December 05, 2022 Filed Dec 8, 2022 01:02 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantRestricted Stock Units · Derivative | 444,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060274 · doc4.xml · derivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,000 Underlying: Common Stock · 444,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The RSUs vest over four years. 25% of the RSUs will vest on December 15, 2023 (the "Annual Vesting Date"), and 25% of the total number of RSUs will vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). F2 · derivative.expiration_date: The RSUs vest over four years. 25% of the RSUs will vest on December 15, 2023 (the "Annual Vesting Date"), and 25% of the total number of RSUs will vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| January 03, 2022 Filed Jan 11, 2022 02:07 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-22-002772 · doc4.xml · derivative · entry 2 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-01-02 F2 · derivative.exercise_date: The shares vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
| January 03, 2022 Filed Jan 11, 2022 02:07 UTC | SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-22-002772 · doc4.xml · derivative · entry 1 Szwarcberg Javier B. · CIK 0001903669 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares subject to the stock option vest over a four-year period commencing January 3, 2022, with 1/4th of the shares vesting on January 3, 2023 and 1/36th of the remaining shares vesting on a monthly basis, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.